- Bayer is committed to providing access to modern contraception for women in low- and middle-income countries, and to working toward the United Nations Sustainable Development Goals (SDGs).
- The new state-of-the-art pharmaceutical plant, which will produce long-acting reversible contraceptives (LARC), is already under construction in the Coyol Free Trade Zone, in Alajuela.
- For Bayer, Costa Rica offers an excellent and strategic location, paired with qualified talent, sustainability policies, and the conditions necessary for private investment.
Bayer recently announced a $200 million (€170 million) investment in Costa Rica, which will provide access to family planning for more women in low- and middle-income countries. In the Coyol Free Zone, in Alajuela, construction is already underway on a new pharmaceutical plant for the production of long-acting reversible contraceptives, such as hormonal implants and intrauterine systems (IUS). The result will be a state-of-the-art pharmaceutical facility, which is expected to begin production in 2024 and will work in coordination with other Bayer plants around the world.
Among Bayer’s sustainability commitments, it is important to both empower women and support their family planning and self-determination. At the 2019 International Conference on Population and Development, Bayer announced its goal, by 2030, to provide 100 million women in low- and middle-income countries with access to modern contraceptives, as part of its contribution to the United Nations’ Sustainable Development Goals (SDG). Their investment, announced today, contributes significantly to this commitment.
Carlos Alvarado, the President of Costa Rica, commented: “This is an emblematic project, in every way: The magnitude of the investment. The scale and ambition to improve access, to tens of millions of women, to modern methods of family planning. And the huge vote of confidence, from a world giant in innovation and quality, for Costa Rica’s human talent, our investment climate, and institutional framework. For this and much more, this investment will mark a before and after, both in the sector and in the consolidation of our successful and dynamic life sciences cluster.”
President Alvarado concluded, “Here, we witness the convergence of the things we work toward, every day. As a country, Costa Rica increasingly attracts more foreign investment and creates high-quality jobs, based on our human talent and our deep commitment to sustainability, thus creating a unique value proposition for investment with purpose, as well as for establishing long-term relationships, such as the one that has united us with Bayer for more than 40 years and that today, we take to another level.”
Christian Meyer, President of Bayer Central America, the Caribbean, and Andean Countries, commented that “our knowledge, scientific research, and new developments in producing long-lasting contraceptives are crucial to achieving our commitment to sustainability. Due to increasing unmet needs for family planning, our current manufacturing network requires an increase in capacity. Based on this need, Costa Rica was selected, thus evidencing the trust that the country instills in us for our businesses, based on its strategic location and valuable human talent offering the knowledge necessary to manage our technology, as well as sustainability policies, such as those that promote the development and capture of private investment.
“We want to demonstrate, once again, the commitment we have in this country so important to our region,” continued Meyer. “We have grown, thanks to Costa Ricans and over our more than 40 years together, working in the country, where we also operate a medical device plant in Heredia, a shared services center that serves the entire American continent (except Brazil), and two plants dedicated to agricultural sector research and development.”
Andrés Valenciano, Costa Rican Minister of Foreign Trade, stated: “Today is a historic day for the foreign trade sector, for our country, and especially for Costa Ricans. We celebrate the announcement that one of the world’s leading life sciences sector companies continues to grow in our country. We appreciate the trust they have placed in us, as well as the opportunities for well-being and development they offer our population. As a country, we understand the language of business and we work to continue cultivating a synergy of growth and mutual development. Costa Rica is a small country with big minds and the desire to make a difference. Having allies like Bayer means that, together, we can continue to build a more sustainable and inclusive nation.”
Jimmy Suazo, manager of the new Bayer Medical Alajuela site, which is estimated at approximately 28,000 square meters (300,000+ square feet) of construction and 6 production lines, furthered, “the plant is expected to employ around 250 people upon launch of its operations, with increasing hiring needs as our production also increases. Additionally, I would also like to highlight that Costa Rica’s permanent commitment to sustainability aligns with Bayer’s sustainability commitments – another fundamental point that supports today’s announcement of why we’re investing in Costa Rica.”
Jorge Sequeira, Managing Director of CINDE, commented, “Bayer’s investment, in this pharmaceutical industry and medical device manufacture megaproject, positions us as a country where companies with purpose can take advantage of the sustainability conditions that we offer to enable responsible production. From Costa Rica, the company will produce the third-largest product in its biopharmaceutical division, empowering Bayer to respond to global demand and simultaneously positioning us as a global benchmark for the industry. Bayer confirms that they chose Costa Rica as the site of investment, after gathering the technical and competitive capacities required for the operation, under the pillar of sustainability.”
Products from the Costa Rican plant will be destined for international organizational programs, such as the United Nations Population Fund (UNFPA) and the United States Agency for International Development (USAID), since they have recently added Bayer’s hormonal IUS to their respective catalogs and will be in charge of defining the countries, as well as coordination and distribution according to their needs. “I am proud to say that, through our work, we will give women the opportunity to define their own futures, as planning allows them to form healthier families and creates a positive domino effect on health systems, our countries’ economies, and societal welfare, in general,” Suazo concluded.
About Bayer
Bayer is a multinational company with key competencies in the bioscientific fields of health and food. Its products and services are designed to help people and the planet prosper, by supporting efforts to overcome the major challenges posed by a growing and aging world population. Bayer is committed to driving sustainable development and thus creating a positive impact on its business. At the same time, the Group aims to increase its purchasing power and create value through innovation and growth. Around the world, the Bayer brand is synonymous with trust, reliability, and quality. During the 2020 fiscal year, the Group employed some 100,000 people and recorded sales of €41.4 billion. R&D expenses before extraordinary items amounted to €4.9 billion.
For more information, visit www.bayer.com or www.cinde.org
